Repurposed Therapeutics

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Repurposed Therapeutics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 2 currently recruiting 5 completed top decile by trial count

Repurposed Therapeutics: 9 sponsored US clinical trials, 2 recruiting.

Repurposed Therapeutics sponsors 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 5 completed. 5 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Motion Sickness, Space, with 2 trials.

Top-decile sponsor footprint

Repurposed Therapeutics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

NCT05886660
RECRUITING Phase 2

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

NCT05852730
COMPLETED Phase 3

Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

NCT05548270
COMPLETED Phase 3

Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

NCT04947423
COMPLETED Phase 3

Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness

NCT04184115
COMPLETED Phase 3

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

NCT03988530
COMPLETED Phase 3

The Prevention and Treatment of Nausea Associated With Motion Sickness

NCT03986905
TERMINATED Phase 2

DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness

NCT04219982
TERMINATED Phase 2

Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray

NCT02155309

Phase Distribution

PhaseTrial count
Phase 2 4
Phase 3 5

Therapeutic Areas

Motion Sickness, Space 2
Parabolic Flight 1
Motion Simulation 1
Sea Sickness 1
Motion Sickness 1

What is open in the Repurposed Therapeutics pipeline

2 recruiting of 9 indexed (22% open); 5 completed (56%).

Phase mix: 5 late (III/IV) vs 4 early (I/II) (balanced across stages).

Top condition: Motion Sickness, Space (2 trials), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Repurposed Therapeutics: open-pipeline peers nationwide

Peers matched on 9 registered trials and 22% open enrollment, not the therapeutic-area sidebar.

Repurposed Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 8101214161820 0%10%20%30%40%50% Total trials Recruiting share Repurposed Therapeutics4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyALX OncologyBiosense WebsterEnglewood Hospital and Medical CenterEnsysce Biosciences
Repurposed Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Repurposed Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 22% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Repurposed Therapeutics page

9 registered trials is a research-attention snapshot, not an endorsement of Repurposed Therapeutics or any single study.

  • 2 of Repurposed Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Motion Sickness, Space is the condition Repurposed Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Motion Sickness, Space trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Repurposed Therapeutics pipeline card: 9 registered trials from official public datasets.Report a data error.